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Antibiotics are added to animal feeds as prophylactic agents and to encourage
weight gain in livestock. However, there is concern that the widespread use of antibiotics
in animal agriculture encourages for the selection of resistance genes and has contributed
to the rise of multiply antibiotic resistant strains of pathogenic bacteria. For this reason,
there is interest in quantifying antibiotics in environmental samples. The determination of
three antibiotics in swine waste, namely chlortetracycline, tetracycline and
oxytetracycline, using LC-MS with electrospray ionization is presented here in.
Antibiotics from swine waste were quantified across the lifespan of the swine. Trends
were present in each of the four life stages (gestation, farrowing, nursery, and finishing).
The nursery stage of life presented the most dominate concentrations and the most
consistent trend in antibiotic concentrations.

viii

I.

INTRODUCTION
A. Background
One of the growing topics in veterinary medicine is the use of antibiotics in

livestock feeds, which have environmental impacts caused by the use of the waste as
fertilizer on fields in which crops are grown and ground water run-off. These antibiotics
are the center of a growing controversy over the widespread use of antibiotics creating
dangerous antibiotic-resistant bacteria. This thesis deals with swine production and the
affects antibiotics have on swine by utilizing research that has been conducted with solid
phase extraction and liquid chromatography mass spectroscopy (LCMS) methods.
Antibiotic means “against life” or “destructive to life”.1 A more extensive
definition of antibiotic is a substance produced by, or derived from, a living organism.1
Most antibiotics that are being used in medicinal treatment are produced from various
bacteria or mold, some microorganisms even produce their own antibiotics that will kill
other organisms. Antibiotics can be further classified by the way they interact with the
organism they are trying to kill. These types of antibiotics along with their characteristics
are shown in table 1. It should be noted that each of these antibiotic categories can be
broken down again into more specific variations. For example, chlortetracycline is a
form of a tetracycline.
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Table 1. Types of antibiotics and their characteristics1
Antibiotic
Penicilin and Bacitracin

Characteristics of Antibiotic
Agents that act of the cell wall on the
bacteria.
Agents that have degenerate effects on the
cell membrane.
Agents that interfere with protein
synthesis.
Agents that affect nucleic acid and
metabolism.

Polymyxin and Novobiocin
Tetracyclines and Streptomycin
Griseofulvin

It is estimated that in the United States over 24.6 million pounds of antibiotics are
used for nontherapeutic purposes or without a known infection present.2 Antibiotics can
be administered to the animal in several different forms either by injection or by
feed/water additive. The most common type of introduction is through the addition of
antibiotics to feedstocks. There are at least eleven antibacterial or antifungal compounds
widely used as feed additives swine. These compounds are various salts of bacitracin,
chlortetracycline, dynafac, mycostatin, oxytetracycline, oleandomycin, penicillin,
streptomycin, bambermycins, tilmicosin, and tylosin.1 The three classifications of
antibiotics that are the most common and the most risk for overlapping between human
and livestock are tetracycline, erythromycin, and penicillin.
These antibiotics are typically added to feed for the purpose of greater and faster
growth of the animal. Specifically in swine, antibiotics mainly alter the microbial
population of the intestinal tract. The antibiotics can affect the swine in three ways:
enhancing the growth of intestinal organisms that synthesize the nutrients required in an
animal, depressing the growth of organisms that compete with the host organism for
nutrients, and reducing the intestinal wall thickness, potentially improving the intestinal
absorption of nutrients.
2

With a solid understanding of what antibiotics are and how they are introduced to
swine, it is easier to understand how they can be detrimental to humans. The main
concern about antibiotics being used in excess in swine production is the increasing
abundance of antibiotic resistance and the transfer of resistance to pathogens.3 The
antibiotics that are being used in the production of swine are suspected to be producing
antibiotic-resistant bacteria that are being excreted from the animals in their waste. This
waste is then spread on fields as fertilizer and can contaminate run off water. There have
been countless studies reviewing this issue. The Food and Drug administration (FDA)
and other government agencies are currently responding to these concerns.
The Government Accounting Office (GAO) stated in the April 1999 report, “The
Agricultural Use of Antibiotics and Its Implications for Human Health,” that
“in light of the emergence of antibiotic resistance in humans, questions about the
extent that the agricultural use of antibiotics contributes to the human health burden, and
the debate over whether further regulation or restriction of use in agriculture is needed,
we recommend that the Secretaries of Agriculture and of Health and Human Services
develop and implement a plan that contains specific goals, time frames, and resources
needed to evaluate the risks and benefits of the existing and future use of antibiotics in
agriculture, including identifying and filling critical data gaps and research needs.”4
This was the first step a government agency had in the influence of what
antibiotics were to be used in livestock feed and how they were to be regulated.
“However, the House and Senate committees on Appropriations agreed with the
GAO and immediately stated that they wanted to conduct a risk assessment of the human
health risk linked to on-farm antimicrobial use. The House committee took it a step
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further and decided they would also like to direct a report comparing the risk of
resistance in foodborne pathogens from the on-farm use of antimicrobials with that of the
other uses of antimicrobials.”4
The interest in the new concern grew, and continued to grow, eventually getting
several different agencies involved.
In 1999 the Council of Food and Safety began to look at this issue in more broad
terms. The concern was no longer just food safety but all aspects of resistance as a public
health program. These broader approaches lead to the publication of “Draft Public Health
Action Plan to Combat Antimicrobial Resistance,”4 which was a framework for goals to
be achieved within several years. The Draft assessed agricultural antimicrobial use and
examined the problem of resistance as a food safety issue. With the broader definition of
the assessment, specific agencies took on different sides of the issues. An example of
this is the Center for Veterinary Medicine taking over the responsibility of health risks
that are posed by the use of antimicrobial drugs in livestock production. They would look
specifically into the pathogen/drug/outcome combinations using data that came from the
research.
B. Government Recommendations
The Draft Action Plan4 proposed goals of how to determine if the antibiotics
being used in livestock production can be harmful to human beings. The first division of
the goals was under the Surveillance tab. The main goal that was presented in this section
was to develop and implement procedures for monitoring patterns of antimicrobial drug
use in human medicine, agriculture and consumer products. The next section was
Prevention and Control; the goals for this section were to develop and implement a public
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education campaign to promote judicious antimicrobial use as a national health priority.
There were two other suggestions in this division. The first was to disseminate and
evaluate clinical guidelines that address judicious antimicrobial use. The next suggestion
was to refine and implement the new proposed framework by the FDA. This framework
is for new antimicrobial drugs that are used in livestock production. In the Research
Section there are two recommendations for improvement. The first recommendation is to
provide all technologies required to identify the emerging resistant pathogens. The
second of these recommendations is to develop and test rapid diagnostic methods. The
last section with recommendations is product development; this section has two
recommendations. The first of these is to create a product development working group
whose purpose is to promote the priority of public health needs. The second
recommendation was to be able to talk to the different communities about the products
that can be helpful in the markets that purchasing incentives are not working well”4
The FDA released an article by the title Framework Document5; this document
addresses increasing resistance to antimicrobial drug treatment in bacteria that infect
humans. These findings raised the question of how the use of antimicrobial drugs in
livestock production plays a role in the drug resistance of bacteria. The FDA places
blame not only on the use of antibiotics in livestock production but also on the overuse of
antibiotics in human treatment. However, this article expresses the concerns with the
animal production side of the issue.
“FDA is charged with the regulatory responsibility of ensuring that the use of
antimicrobial drugs in food-producing animals does not result in adverse health

5

consequences to humans. Although this is the main charge and responsibility of the FDA
they also understand that antibiotics are essential for the growth of livestock.”5
The need is to have enough antibiotics in the feed for proper growth, but also not
to be so abundant in antibiotics that it is harmful to the animal and humans; they are
looking for a balance between the two.
The FDA released that they needed to evaluate two things in particular. First is
the amount of antimicrobial drug resistant bacteria that are present in livestock intestinal
track after the animal is exposed to a new antimicrobial drug. The second is the amount
of bacteria in the animal’s intestines that is considered harmful to humans. When an
antimicrobial antibiotic is used, the bacteria that are the most sensitive to the drug are
inhibited. These bacteria can then mutate or acquire the ability to be able to resist the
antimicrobial drug; this can be especially detrimental to humans if the bacteria are
disease-causing. A bacterial strain that is antibiotic resistant in livestock has the potential
to be resistant in humans. It is also possible that bacteria that is not pathogenic to
animals, is pathogenic to humans, is passed on by eating the animal. Three very good
examples of how this can occur are Salmonella, Campylobacter, and E. coli O157. All
three of these can be found in animal products and are not be pathogenic to the animal;
however, they are pathogenic to humans. It is very well known that the most likely
source of most antimicrobial resistance is the use of antimicrobials in food-producing
animals.
The FDA also states that they not only need to be worried about animals
becoming resistant to one specific pathogen, but that the process of how the bacteria is
attacked might change the interaction of the bacteria in the animals intestine track.
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“This therapy may also disturb the normal intestinal microbial ecosystem in the
animal, resulting in an increase in the bacteria that can cause human infections or
prolonging the duration of the carrier state of such bacteria (pathogen load). Animals
carrying increased amounts of pathogens at the time of slaughter present an increased risk
for contamination of food and resulting human illness. To keep this from potentially
happening, the FDA currently requires applicants for over-the-counter uses of
antimicrobials --------like those--------that will be administered as a feed additive for
more than fourteen days--------- submit, as part of their safety data, the results of
preapproval studies intended to detect the development of antimicrobial resistance in
enteric bacteria from treated animals.” 5
The five goals listed by the FDA for evaluating and maintaining safety are:
“1) assessing the effect of proposed uses on human pathogen load;
2) assessing the safety of proposed animal uses of drugs according to their (or
related drugs) importance in human medicine and the potential human
exposure to resistant bacteria acquired from food-producing animals that are
human pathogens or that can transfer their resistance to human pathogens;
3) assessing pre-approval data showing that the level of resistance transfer from
proposed uses of drugs, if any, will be safe;
4) establishing “resistance” and “monitoring” thresholds to ensure that approved
uses do not result in resistance development in animals or transfer to humans
above the established levels; and
5) establishing post-approval studies and monitoring. 5
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When assessing the resistance of bacteria from antimicrobial antibiotics that are
used in livestock intended for human consumption, there are two important factors:
1) The importance of the drug or drug class in human medicine
2) The potential human exposure to resistant bacteria acquired from foodproducing animals that are human pathogens or that can transfer their
resistance to human pathogens. 5
These two factors lead to the FDA coming up with three categories for the
antibiotics based on the importance of the drug or its use in human medicine, potential
human exposure, and resistance to human pathogenic bacteria. The FDA claims that by
dividing the antimicrobial antibiotics into categories, it will be more efficient to learn
more about them and to maintain long-term safety and stability. Table 2 (next page)
describes the criteria for each category.
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Table 2: Requirements to be in each category5
Category I
1) Essential for treatment of a serious or life
threatening disease in humans (conditions of high
morbidity or mortality) for which there is no
satisfactory alternative therapy.
2) Important for the treatment of foodborne
diseases in humans where resistance to alternative
antimicrobial drugs (e.g., Category II drugs) may
limit therapeutic options (recognizing the special
risks of both resistance development in, and
transmission to, humans of foodborne pathogens).
3) The drug is a member of a class of drugs for
which the mechanism of action and/or the nature
of resistance-induction is unique, resistance to the
antimicrobial drug is rare among human
pathogen(s), and the drug holds potential for long
term therapy in human medicine.
In addition, any antimicrobial that can induce or
select for cross-resistance to a Category I drug
would be considered a Category I drug. Similarly,
if an antimicrobial is not used in human medicine,
and if it could be demonstrated to the agency's
satisfaction that it does not induce crossresistance to any antimicrobials in the same class
used in human medicine that are Category I, then
it would not be considered a Category I drug.
The following are examples of types of drugs that
would be included in Category I:
1) Quinolones for serious infections caused by
multi-drug resistant Salmonella spp. (resistant to
Category II drugs). Quinolones are often the
primary treatment for salmonellosis, which in the
U.S. generally is food borne. Quinolones are also
the drugs of choice and alternative therapies for
many life-threatening resistant gram negative
infections.
2) Vancomycin for serious infections (e.g., sepsis,
pneumonia, endocarditis) caused by methicillin
resistant S. aureus, and ampicillin resistant
enterococci. Vancomycin is the only well proven
treatment drug available to treat serious infections
with these organisms.
3) Dalfopristin/quinupristin (Synercid) for
vancomycin-resistant enterococcal infections.
Additionally, Synercid has an unique mechanism
of action. It was presented to an FDA Advisory
Committee in February 1988.
4) Third generation cephalosporins used to treat
foodborne infections (e.g., ceftriaxone for
Salmonellosis in children).

Category II
1) Ampicillin for
treatment of infections
due to Listeria
monocytogenes. The
disease is life threatening;
however, alternative
therapies are available
(e.g., trimethoprimsulfamethoxasole).
2) Cephalosporins not in
Category I which do not
induce cross resistance to
those in Category I; beta
lactams and beta
lactamase inhibitor
combinations because
they represent both drugs
of choice and alternative
therapies for many life
threatening gram negative
infections.
3) Erythromycin for
treatment
of Campylobacter infectio
ns.
4) Trimethoprimsulfamethosaxole for
treatment of a wide range
of serious enteric
infections including
susceptible Salmonella an
d Shigella infections.
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Category III
1) They have little or no
use in human medicine.
2) They are not the drug
of first choice or a
significant alternative for
treating human infections
including food borne
infections.
The following are
examples of type of
drugs that would be
included in Category III:
1) Ionophores (e.g.,
monensin) which
currently have no usage
in human medicine
2) The polymixins (e.g.,
Polymixin B and
colistin) since they have
significant toxicities and
have been supplanted by
other drugs for virtually
all human use.

The FDA started its evaluation of antimicrobial antibiotics with category I at the
highest importance because of the high potential of resistance being developed in
humans. They suggest obtaining threshold levels and then continuing to monitor these
levels as the drugs may continue to change. The same suggestion is recommended for
category II drugs though risk to humans is not as high. Category III drugs are thought to
be at a low risk of being harmful to humans at this time. These recommendations are for
both traditional pharmaceuticals as well as agriculture. Monitoring of the farm is
necessary to make sure that the guidelines are being followed, and that no excess
pathogenic bacteria are being unintentionally released in the environment for human
consumption.
The FDA has clearly stated that more research needs to be conducted and
standards set; however, the FDA is not the only group performing research at this time.
As the FDA stated, their goals will take several years to achieve, but outside sources have
been doing research on several factors of how humans are already being impacted with
pathogenic bacteria. For example, there have been several studies on ground water runoff
containing bacteria; there have also been studies on bacteria in soil.
C. History of Tetracycline
Tetracycline refers to a family of antibiotics with similar structures; the most
common antibiotics in this family are shown in table 3.
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Table 3: List of most common compounds in the tetracycline family.6
Chemical Name

Generic Name

Trade Name

Status

Aureomycin
Terramycin

Yr of
discovery
1948
1948

Tetracycline
Demethylchlortetracycline

Achromycin
Declomycin

1953
1957

Marketed
Marketed

Therapeutic
administration
Oral
Oral and
Parenteral
Oral
Oral

7-Chlortetracycline
5-Hydroxytetracycline

Chlortetracycline
Oxytetracycline

Tetracycline
6-Demethyl-7chlortetracycline
2-NPyrrolidinomethyltetracycline
2-NLysinomethyltetracycline
N-Methylol-7chlortetracycline
6-Methylene-5hydroxytetracycline
6-Deoxy-5hydroxytetracycline
7-Dimethylamino-6demethyl-6-deoxytetracycline
9-(t-butylglycylamido)minocycline

Rolietracycline

Reverin

1958

Marketed

Oral

Limecycline

Tetralysal

1961

Marketed

Clomocycline

Megaclor

1963

Marketed

Oral and
parenteral
Oral

Methacycline

Rondomycin

1965

Marketed

Oral

Doxycycline

Vibramycin

1967

Marketed

Minocycline

Minocin

1972

Marketed

Oral and
parenteral
Oral and
parenteral

Tertiarybutylglycylamidominocycline

Tigilcycline

1993

Pahse II
clinical
trials

Marketed
Marketed

TThree members of the tetracycline family that were of interest in this study were
tetracycline, chlortetracycline, and oxytetracycline. The tetracycline family is known for
having the same core structure with different function groups to make different forms of
the family of tetracycline. The simplest form of the tetracycline family is 6-deoxy-6demethyltetracycline (Figure 1).

Figure 1: The structure of 6-deoxy-6-demethyltetracycline6
N(CH3)2
H
6
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OH

5

B

C

D

H
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OH

1

CONH2

A
12
OH

O

11

The basic structure shows the four fused rings labeled A, B, C, and D that
compose the core of the tetracycline family. Specific zones of structural importance for
antibacterial activity are “steriochemical configurations at 4a, 12a (A-B ring junction),
and 4(dimethylamino group) positions, and conservation of the keto-eno system (position
11, 12, and 12a) in proximity to the phenolic D ring.”6 The tetracycline structure is
known for being affected by the chelation of metal ions at “the b-diketone system
(positions 11 and 12) and the enol (positions 1 and 3) and carboxamide (position 2)
groups of the A ring (20, 44).”6
The tetracyclines are a large family of similarly structured drugs. There are
multiple pKa values for each one due to multiple functional groups that can be attached
to core structure of the antibiotic. Tetracycline has three pKa values: 3.3, 7.7, and 7.9
the reason for these three different pKa values can be shown in figure 2 with the
highlighted boxes.

Figure 2: The structure of tetracycline7.
H3C
NH

CH3
H

HO

CH3

H
OH

NH2
OH
OH

O

OH

O

O
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The structure of chlortetracycline is shown below in figure 3. Chlortetracycline
also has three pKa values: 3.3, 7.4, and 9.3.

Figure 3: Structure of chlortetracycline.8
OH

OH

O

OH

O
OH

NH2

O
H
CH3

HO

Cl

H
N
H3C

CH3

The structure of oxytetracycline is shown below in figure 4. Oxytetracycline’s
pKa values are 3.3, 3.7, and 9.1.

Figure 4: Structure of oxytetracycline7.
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O

OH
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H
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OH
HO
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OH
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CH3

When looking for the tetracycline ions it is very important to note the parent ion
and the precursor and product ion; this is because when setting the MS/MS parameters on
the LCMS the product ion may provide a more defined peak than the precursor ion. Thus
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being the values used to set the ions that are being looked for; these values can be seen in
table 4.

Table 4: Precursor and product ions.9
Name
Tetracycline
Oxytetracycline
Chlortetracycline

Precursor Ion
445
461
479

Product Ion
410, 427
426, 443
444, 462

D. Proposed Research
The research conducted addressed the issue of the swine containing antibiotics
and then the waste being spread on fields or used in other forms that would cause an
environmental impact that is harmful to humans. The research studied the levels of
antibiotics in swine waste across the lifespan of the swine.

II.

EXPERIMENTAL
A. Sampling Plan
The purpose of this project is to analyze swine waste for antibiotics across the

time span of the swine production process. The chosen swine farm categorized the pigs
into the following life span sections: gestation, farrowing, nursery, and finishing.
Gestation is the stage were the female swine are impregnated. Farrowing is when the
impregnated female swine give birth and the new baby swine stay with their mother for
several days to a few weeks. Nursery is when the young swine are removed from their
mother. Finishing is the last stage of growth and development before the swine are sent to
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slaughter. All samples were analyzed with LCMS after being processed with a solid
phase extraction method.
The samples were collected on the first day of each week from a swine facility in
Curdsville, Kentucky for several weeks. Samples of approximately 250 mL each were
collected from the gestation, farrowing, nursery, and finishing buildings. Most samples
were collected using a meter-long plastic pipette with a large pipet bulb. Other samples
were collected using a long pole with a plastic bottle attached to the end of it. These
sampling methods can be seen below in the pictures labeled figure 5 and figure 6.
Samples were placed into 500-mL plastic bottles and transported to the USDA lab facility
where they were split before being stored. The sample splits that were taken for LCMS
analysis were stored in a refrigerated environment at four degrees Celsius to reduce
degradation.
Figure 5: Sample Collection

Figure 6: Sample Collection

B. Sample Preparation and Solid Phase Extraction
The samples were prepared by using a USDA Food Safety and Inspection
Service, Office of Public Health Science method titled “Qualitative Identification of
Tetracyclines.”10 This method was written to prepare liver, muscle and kidney samples of
fish and poultry. Due to the solids and dirtiness of all the samples, this procedure was
15

thought to work for the waste samples. The samples were then processed with solid phase
extraction to remove solids before injection into the LCMS.
The samples were prepared for solid phase extraction by removing the majority of
the solids via shaking and centrifuging the samples with a Mcllvaine/EDTA buffer The
Mcllvaine/EDTA buffer was made by combining Mcllvaine buffer with sufficient
disodium EDTA dihydrate to give a 0.10 M EDTA concentration. Mcllvaine buffer is a
mixture of 0.20 M dibasic sodium phosphate and 0.10 M citric acid in a 5:8 ratio whose
pH is adjusted to 4.00±0.05.
Ten mL of sample and 20 mL of Mcllvaine/EDTA buffer were added to a 50-mL
centrifuge tube. This tube was then shaken for ten minutes at 450 revolutions per minute,
and then centrifuged for 10 minutes at 2500 revolution per minute. Once the samples
were centrifuged, the supernatant was poured off into a second centrifuge tube. An
additional 20 mL of Mcllvaine/EDTA buffer was added to the residue left in the bottom
of the first centrifuge tube and the shaking and centrifuging repeated. After the second
shaking and centrifuging was complete, the second supernatant was added to the first
supernatant. The supernatants were than centrifuged for 20 minutes at 4000 revolution
per minute. The centrifuge tube was then stored 4°C until ready for further processing.
The last step before solid phase extraction was filtration through a Büchner flask to
remove any bugs or other debris left in the supernatant of the sample after the shake table
and centrifuge steps.
The solid phase extraction cartridges were placed onto a vacuum block apparatus
so they would be under vacuum while performing the extraction, this is shown below in
figure 7.
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Figure 7: Picture of vacuum box used for solid phase extraction.

The cartridges were conditioned with 10 mL of methanol followed by 20 mL of
distilled water. The samples were then loaded onto the cartridge and washed with an
additional 20 mL of distilled water. The cartridges were then allowed to dry under
vacuum for two minutes. At this point the vacuum block would be filled with waste
liquid that was removed before the sample was eluted from the cartridge. Ten-mL
transfer vials would be inserted to collect the sample as it was eluted from the cartridge.
Once transfer vials were put in place to collect the eluted sample, 6 mL of 0.01 M
methanolic oxalic acid solution were added to the cartridges to elute the sample.
The samples that were collected were blown down to 0.5 mL with high purity
Argon, using an evaporator instrument. The sample was then brought back to 1 mL with
methanol and 1 mL of LCMS grade water was added. The 2-mL sample was passed
through a 0.2-μm syringe filter and into a 2-mL LCMS auto sampler vial.
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All samples, including calibration curve samples, were processed in this fashion
to make certain that loss on the cartridge was taken into account when calculating the
concentration. A calibration curve was also run every day that samples were run.
C. Liquid Chromatography Mass Spectroscopy Methods
Once the samples were prepared for the liquid chromatography mass spectrometer
(LCMS) they were loaded into the auto sampler and run on the LCMS with the
appropriate methods. The LCMS that was used for this research was an Agilent 500 ion
trap LC/MS. With this specific instrument and the antibiotics that were being observed, it
was not possible to run a MS/MS method that would be able to detect all three antibiotics
properly. This is due to the retention times of the antibiotics being too close together. The
instrument would need at least two minutes between retention times to properly switch
the ion count. For this reason, three injections were necessary to analyze the three
antibiotics.
For all three methods, the column, mobile phase, and pump settings were the
same. The column was a Varian C18 100×2.0 mm column. The two mobile phases were
LCMS grade acetonitrile and an ammonium acetate and trifluoroacetic acid (TFA)
solution. The solution was 0.05 M ammonium acetate/0
005 M TFA in LCMS grade water. These solutions were then mixed through the pumps
with the ratios shown below along with the Gradient Method that was used; in table 5.
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Table 5: Gradient Method
Time (min:sec)
0:00
2:00
2:06
7:00
7:06
9:00

Percent Ammonium Percent Acetonitrile
Acetate Solution
90
10
90
10
50
50
50
50
90
10
90
10

Flow (μL/min)
225
225
225
225
225
225

The pump settings are the same for all three methods; however, for the MS/MS
parameters the three antibiotics settings’ differ greatly and are listed below in table 6.
These parameters were set based on the data that was obtained by optimizing all the
antibiotic standards separately.
When samples were injected into the LCMS it was very important to clean the
LCMS due to the matrix of the samples that was being injected. The electron spray
ionization (ESI) trap was cleaned with methanol daily; the ion trap was cleaned once a
month following the directions provided by the manufacturer.
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Tetracycline

Chlortetracycline

426

410

462

Product (m/z)

50

50.0

70.0

Cabilary voltage

55

55

55

Rf Loading(%)

3.0

3.0

2.5

Isolation Window
(m/z)

0.0

0.0

0.0

Low Offset (m/z)

0.0

0.0

0.0

High Offset (m/z)

100

100

100

Resonant

Resonant

Resonant

High Mass
Ejection
Factors(%)
Waveform Type

187.7

180.6

203.0

Excitation Storage
Level (m/z)

0.20

0.20

0.20

Excitation
Amplitude (volts)

10

10

10

Excitation Time
(msec)

Yes

Yes

Yes

Modulate RF

1

1

1

Number of
Frequencies

0

0

0

CISD Frequency
Offset (kHz)

188

181

204

Product Ion Start
Mass (m/z)

436

420

472

Product Ion End
Mass (m/z)

No

No

No

More Ranges
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Table 6: MS/MS Parameters for each antibiotics.

Oxytetracycline

III.

Results
The samples discussed here were run in two different batches, using two different LC

MS systems. The first batch was analyzed on the LCMS owned by Western Kentucky
University between May 2013 and August 2013 and has the ion tag of 56. These samples
are referred to and discussed as batch one. The second batch of samples was analyzed on
a LCMS system owned by Agilent Technologies that was loaned to Western Kentucky
University. These samples have an ion tag of 57 and were analyzed between January
2014 and March 2014. These samples are referred to and discussed as batch two. The
same HPLC methods were used on both systems; however, the MS ion tag recognition
was different as noted above and a diverting method was added to batch two to eliminate
the sample from entering the mass spectroscopy system during the full scanning time of
the method. Instead, the sample was only entering the mass spectrometer during the
window the antibiotic was eluting and being detected.
A. Calibration Curves
Calibration standards were analyzed each day samples were analyzed because the
area count of the standards changed on a daily basis. These daily calibration curves were
used to determine the concentrations of the samples across all four life cycles. Calibration
standards were only analyzed for the specific antibiotic analyzed on that day. The
calibration curves consisted of ten standards with known concentrations of 0.05, 0.075,
0.10, 0.25, 0.50, 0.75, 1.0, 1.25, 1.50, and 1.75 ppm. These standards were fit to a linear
model, and the equation from the model was used to calculate the concentration of the
swine samples. Figure 8 shows a typical calibration curve that was used to determine the
concentration of chlortetracycline on July 25th, which was a part of batch one.

21

Figure 8: Calibration curve example: July 25th Chlortetracycline Batch One
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Scatter plots with linear fits for all batch 1 and batch 2 calibration curves are
shown in succession below. Figures 9 and 10 show all of the chlortetracycline calibration
curves for batch one and batch two, respectively. Figures 11 and 12 show all of the
tetracycline calibration curves batch one and batch two, respectively. Figure 13 shows all
of the oxytetracycline calibration curves for batch one.
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Figure 9: All calibration curves for batch one chlortetracycline.
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Figure 10: All calibration curves for batch two chlortetracycline.

Ppm

Chlortetracycline Calibration Curves
Batch Two
400000
350000
300000
250000
200000
150000
100000
50000
0

18-Feb
19-Feb

0

0.5

1
Concentation (ppm)

23

1.5

2

Figure 11: All calibration curves for batch one tetracycline.
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Figure 12: All calibration curves for batch two tetracycline.
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Figure 13: All calibration curves for batch one oxytetracycline
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B. Gestation
Samples were analyzed in all batches for the gestation stage, tetracycline and
chlortetracycline in batch one and batch two, and oxytetracycline in batch one.
Concentrations are shown in bar graphs with their standard deviations as error bars for all
samples.

Figure 14 shows batch one oxytetracycline for the gestation stage. Detection of
antibiotics was expected in this stage of life due to the swine becoming pregnant at this
stage. Swine would need to be in the top health to be able to conceive and have healthy
off spring. The concentration of the antibiotic increased from the start of May through the
end of August; there were a few weeks when the concentration dropped but the general
trend was upward. The concentration varied from 0.62 to 3.02 ppm. This was not the
highest concentration of antibiotics across the lifespan of the swine, but it was the highest
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concentration that was detected in the gestation phase. Tetracycline was detected, but not
at the high levels found for oxytetracycline.

Figure 14: Bar graph of gestation oxytetracycline batch one
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The gestation stage batch one tetracycline data are shown in figure 15. The
highest tetracycline level that was detected was on the week of July 8th and it was just
over 0.40 ppm. This was very surprising with the levels of the oxytetracycline that were
present. What was even more surprising was the level of chlortetracycline that was
detected.

Figure 15: Bar graph of gestation tetracycline in batch one.
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The gestation batch one chlortetracycline is shown in Figure 16.
Chlortetracycline was only detected in two of the gestation batch one samples, both in the
month of August and at just above 0.4 ppm. This indicated that chlortetracycline was not
present in the moths that were surveyed.

Figure 16: Bar graph of gestation chlortetracycline in batch one.
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At the end of August 2013, the original LCMS instrument, on which all batch one
samples were run, became inoperable. The only difference between batch one and batch
two are the LCMS system that was used and the LCMS diverting method being used.
The samples that were prepared were stored in a deep freeze at -80°C in ultraviolet light
protected boxes. These black boxes and the temperature level were chosen to help
prevent light from degrading samples. When the samples were run on the loaner
instrument from Agilent Technologies (batch two), the results that were obtained were
drastically different from batch one. This is shown in figures 17 and 18.
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Figure 17: Bar graph of gestation chlortetracycline in batch two.
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Figure 18: Bar graph of gestation tetracycline in batch two.
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Both the chlortetracycline and tetracycline concentrations from batch two are
significantly higher than in batch one. The chlortetracycline went from below detection
limits approximately 3 ppm, with the higher concentrations in June and July, early in the
gestation stage. The concentration dropped just below 0.50 ppm for August and
September. This was still higher than the highest concentration of chlortetracycline found
in batch one. The tetracycline results were also higher, jumping from being below 1 ppm
to above 10 ppm on average.
There are several reasons that this could have occurred, primarily they are the
difference in instrument and the time. The difference in instrumentation was due to the
first LCMS being contaminated by the samples. This was suspected and confirmed by
documented on a daily basis the ion count time both in full scan and in MS/MS scan on
the loaner LCMS. The samples that were injected into the instrument were found to be
contaminating the instrument. At some point during batch one, the instrument was
contaminated, but the exact time is not known. This could have caused the low
concentrations that were detected, and could explain the apparent absence of
chlortetracycline from batch one that was then detected in batch two.
It should also be noted that the samples that were run in batch one and in batch
two are the same samples. Unfortunately, it is not known how long samples can be stored
without adversely affecting them. They were stored in deep freeze and in ultraviolent
protected boxes to prevent degradation, but it is not knows what is adequate to fully
protect the samples.
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C. Farrowing
Samples were analyzed in all batches for the farrowing stage, tetracycline and
chlortetracycline in batch one and batch two, and oxytetracycline in batch one. Figure 19
shows the oxytetracycline in the farrowing stage. The oxytetracycline was only slightly
lower than it was in the gestation stage (figure 14) because at this stage the sows are
giving birth and the piglets need to be as healthy as possible to be able to survive.

Figure 19: Bar graph of farrowing oxytetracycline in batch one.
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Tetracycline from farrowing batch one is shown in figure 20. The tetracycline in
the farrowing stage is somewhat higher than in the gestation stage (figure 15). The
gestation stage tetracycline peaks about 0.40 ppm and the farrowing stage peaks above
1.0 ppm. This may be due to the stage of life, as the piglets are preparing to leave their
mother and be on their own in the nursery stage. When this occurs, they will no longer be
able to get antibiotics through by nursing; instead, they will have to get it from other
sources such as feed and water.

Figure 20: Bar graph of farrowing tetracycline in batch one.
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No chlortetracycline was detected in batch one; all the peaks were too small to
quantify. Batch two has higher levels of tetracycline and shows levels of chlortetracycline
that were not detectable in batch one. Tetracycline batch two and chlortetracycline batch
two are shown in figures 21 and 22, respectively.
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Figure 21: Bar graph of farrowing tetracycline in batch two.
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The concentration of farrowing stage tetracycline was significantly higher in
batch two than in batch one (figure 20). In batch one the highest was just above 1.0 ppm
while the highest in batch two was over 12 ppm. The trends in both batch one and batch
two are similar, though not identical. They both increase, but batch two is not as drastic
as batch one (as a percentage of the maximum). The other difference is the samples from
August and September were not analyzed in batch one. They were analyzed in batch
two, and they have high concentrations.
The farrowing chlortetracycline batch two was determined to be from 0.15 to 0.42
ppm in contrast to batch one where all dates were below the detection limit. This can be
attributed to the two different instruments and, perhaps, the storage of the samples
between the days of the analyses.
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Figure 22: Bar graph of farrowing chlortetracycline in batch two.
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D. Nursery
Nursery is the stage in the life of a swine where very high levels of antibiotics
were anticipated to be present due to the young swine being fully removed from their
mothers. At this point, the young swine need to get their bacterial resistance from another
source. It is likely that more antibiotics are added to the swine’s environment through
their feed. Samples were analyzed in all batches for the nursery stage, tetracycline and
chlortetracycline in batch one and batch two, and oxytetracycline in batch one.
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Figure 23 shows the oxytetracycline in batch one for the nursery stage. This stage
has the highest concentration of oxytetracycline. The levels vary from below 1 ppm to
nearly 5 ppm, which is noticeably higher than the other stages of life as expected for this
stage.

Figure 23: Bar graph of nursery oxytetracycline in batch one.
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The chlortetracycline results from batch one are shown in figure 24. The results
for chlortetracycline in batch one are low and somewhat erratic, but that is consistent
with the other batch one results for chlorotetracycline.

Figure 24: Bar graph of nursery chlortetracycline in batch one.
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Figure 25 shows the results for tetracycline in batch one. Nursery tetracycline
batch one was very consistent and grew to a of 1.3 ppm. The climb of the concentrations
was very gradual and then dropped abruptly back to around 0.6 ppm. This was different
than the oxytetracyline in batch one which climbed fell both more evenly. However both
the chlortetracycline and tetracycline in batch two do not match the results in batch one.

Figure 25: Bar graph of nursery tetracycline in batch one.
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Nursery chlortetracycline batch two and tetracycline batch two are shown in figures 26
and 27, respectively. Chlortetracycline batch two is significantly higher than in batch one.
The chlortetracycline not only increased, but on the days when there was none detected in
batch one, it was found above 0.3 ppm in batch two. Tetracycline is also significantly
higher in batch two than in batch one.

Figure 26: Bar graph of nursery chlortetracycline in batch two.
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9/9

Figure 27: Bar graph of nursery tetracycline in batch two.
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Although the tetracycline and chlortetracycline from batch two do not match the
trends from batch one for the nursery stage, they are the highest and most consistent
levels in any stage. This was expected due to the swine being removed from their mothers
and having acquired all their own resistance.
E.

Finishing
The finishing stage was not expected to show any antibiotics or low levels of

antibiotics. This is because in the finishing stage, the swine are completing growth and
development before slaughter and the antibiotics should be out of their systems prior to
slaughter. Samples were analyzed in all batches for the finishing stage, tetracycline and
chlortetracycline in batch one and batch two, and oxytetracycline in batch one.
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Figure 28 shows the oxytetracycline in batch one for the finishing stage. Despite
the hypothesis that the antibiotics would not be present in this stage, oxytetracycline was
consistently present in low levels. There are sampling dates missing in this series due to
the WKU LCMS failing before all of batch one could be analyzed. These samples are
missing throughout the rest of batch one for the finishing stage.

Figure 28: Bar graph of finishing oxytetracycline in batch one.
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Tetracycline batch one for the finishing stage is shown in figure 29. The low
levels tetracycline found here follow the hypothesis that there should be no antibiotics or
low levels of antibiotics present. They are all below 1 ppm of tetracycline. There were
also no detectable levels of chlortetracycline in finishing batch one.

Figure 29 Bar graph of finishing tetracycline in batch one.

Chlortetracycline (ppm)

Finishing Tetracycline Batch 1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
5/28

6/17

6/21

7/1

7/8

Sample Date

41

7/29

8/19

8/26

Finishing batch two for showed low levels of chlortetracycline as seen in figure
30 where the chlortetracycline was present at first and then fell below detection limits.
This followed the expected trend of low to undetectable antibiotics for the finishing stage.

Figure 30: Bar graph of finishing chlortetracycline in batch two.
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However, this trend did not bear out for the tetracycline in the finishing stage as
seen in figure 31. The tetracycline for batch two is very high, averaging above 10 ppm
though the finishing stage. This is very surprising with finishing being the last stage
before slaughter.

Figure 31: Bar graph of finishing tetracycline in batch two.
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IV.

Conclusion
There were several discrepancies in the data that was collected from this study.

The primary result is that there are antibiotics present at detectable levels in swine waste
across the life span of the swine. This is important for the determination of amounts that
are considered safe and appropriate for the production of swine.
The life stage found to produce the most interesting results was the nursery stage
because of it having the highest levels of antibiotics being detected out of every stage.
They also have the most consistent levels across the dates sampled. The nursery section
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needs to be extended not only to test waste but also the food, and water fed to the swine.
This would give us insight into how much antibiotics are going into the animal and the
concentration once it is processed and excreted through the animal.
There were several factors that affected the results of this study and ultimately
lead to the inconsistent results. The main causes are damage that was done to the WKU
LCMS when injecting samples and then switching to the loaner LCMS from Agilent
Technologies.
Instrumentation failures compounded the problem by limiting the span of data
collected. Conducting sampling and analysis over the course of at least nine months
would give a better representation of trends. The current study has samples from late May
to the beginning of September – only about four months. Investigating if the patterns
repeat them across the lifespan of the swine could indicate that the result is not just from
random treatments.
Using two different instruments was a large factor in the differences between
batch one and batch two across the sampling dates. Those large differences make it
difficult to confirm the concentrations of antibiotics detected, leading the conclusion that
antibiotics are present and detectable but the exact concentrations are not certain.
The instrument became contaminated because of the samples used. Additional
filtration or clean-up of the samples should be completed before injecting the samples
into the instrument. The main objective would be to eliminate the yellow/brownish color
that remains in the samples, the components of the sample that are giving the color are
thought to be the contamination source. Agilent Technologies staffs who were consulted
on the instrument problems believe the source of the color of the sample is causing the
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contamination. Agilent made several suggestions on what could be done to reduce the
coloration of the samples. Most of these suggestions include a new method of extraction.
One of the solid phase extractions currently being considered is a silica gel cartridge
instead of the C18 cartridge used in this work.
There are a few other directions in which this work could go.One option is to use
ion exchange solid phase extraction to extract the antibiotics from the samples. This is a
viable procedure because of the different ion charges in the tetracycline structure. . If
using the current extraction method, fractional samples could be collected from the
column in the time range the antibiotics are known to elute. Then those samples could be
diluted and analyzed. This would allow the samples to not be injected into the ion trap for
a longer period of time instead of having to use the diverting method for all times except
when the antibiotic is known to elute. It might also be possible to use solid-phase microextraction (SPME) for a more complete isolation of the antibiotics from the sample.
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